BPC-157 calculators

BPC-157 — short for Body Protection Compound 157 — is a synthetic peptide originally derived from a sequence found in human gastric juice. It is one of the most widely discussed peptides in the research market, primarily because of its long history in animal studies looking at tissue and connective-tissue contexts.

BPC-157 is supplied as a lyophilized powder in vials rated in milligrams of active peptide. Common vial sizes are 2 mg, 5 mg, and 10 mg. Because typical illustrative doses are well below 1 mg, the dose calculator on this page defaults to micrograms — using mg with a typed value like 0.25 makes decimal-place mistakes much more likely than typing 250 mcg.

Unlike the long-acting GLP-1 peptides on this site, BPC-157 is short-acting and is typically logged on a daily — sometimes twice-daily — cadence in most personal logs. That changes the vial duration math significantly: even a small vial covers many doses on a weekly basis.

BPC-157 is studied for its possible effects in tissue and connective-tissue contexts. The mechanistic literature is still developing and there are no peptide-page-appropriate clinical claims to make beyond noting that it remains a topic of active research.

Anyone tracking BPC-157 in a personal log will benefit from pairing the dose history with whatever metric the protocol is targeting — joint comfort ratings, recovery notes, or general wellbeing tracking. As with every peptide, the trend across weeks is what is meaningful, not any single day.

Published research on the mechanisms of BPC-157 frequently centers on its interaction with angiogenesis, the process of forming new blood vessels. Specifically, studies have observed its influence on the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) signaling pathway. In various research models, the peptide has been documented to modulate the activation of this key receptor. This interaction is often studied in conjunction with the nitric oxide (NO) system, as the VEGFR2 pathway and NO synthesis are closely linked. The scientific inquiry focuses on how BPC-157 might influence these cascades, providing a framework for observing its effects at a molecular level without making clinical claims.

Daily subcutaneous injection is the default cadence in most BPC-157 logs, and twice-daily protocols also appear. Doses are small enough that a U-100 insulin syringe is the standard tool.

Cycling — running BPC-157 for a defined number of weeks, then taking a break — is common in personal logs. Recording the start and stop date of each cycle in the log is what makes the timeline auditable later.

Some users inject BPC-157 close to a target area; others prefer rotating standard subcutaneous sites. Either way, recording the injection site in the log is what surfaces site-rotation patterns over time.

A unique consideration when planning a documentation schedule for BPC-157 is the administration route. While subcutaneous injection is common in peptide research, a significant body of preclinical literature on BPC-157 also explores oral administration. This dual-route exploration makes it a critical variable to log for accurate personal tracking. If a protocol involves subcutaneous administration, precise dose calculation is necessary. For example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 2,500 mcg/mL. A 250 mcg illustrative dose is 0.1 mL or 10 units on a U-100 syringe. This dose would be logged with a daily cadence, explicitly noting the administration route (e.g., 'Subcutaneous, left thigh') to distinguish it from any potential oral use.